Please check your internet connection and try again.
# Hepamerz (l-Ornithine l-Aspartate)
## Overview
L-ornithine L-aspartate is a combination of two amino acids, ornithine and aspartate. It is believed to work by stimulating the detoxification of ammonia in the liver and peripheral tissues. It is administered intravenously.
## Primary Indications
Treatment of hyperammonemia in patients with liver insufficiency (e.g., cirrhosis).
## Adult Dosing
* **Initial Dose:** 5 to 10 grams intravenously (IV) infused over 30 minutes.
* **Subsequent Doses:** May be repeated every 8 to 12 hours as needed, up to a maximum of 10 grams every 8 hours.
* Dosing is often guided by ammonia levels and clinical response. Specific titration protocols may vary by institution.
## Pediatric Dosing
There is **limited data** on the use of l-ornithine L-aspartate in pediatric populations. Dosing should be determined by a specialist and administered cautiously.
## Dose Adjustments
* **Renal Impairment:** Use with caution. While the drug is not primarily renally cleared, severe renal impairment may affect ammonia metabolism and overall patient status.
* **Hepatic Impairment:** This is the primary indication; dose adjustments are usually based on ammonia levels and clinical assessment rather than hepatic function itself, as the goal is to improve hepatic function surrogate markers.
## Contraindications
* Known hypersensitivity to l-ornithine or L-aspartate.
* Severe renal insufficiency (this is a relative contraindication and requires caution).
## Adverse Effects
* Nausea, vomiting
* Abdominal pain
* Dizziness
* Electrolyte disturbances (rare)
* Injection site reactions (pain, phlebitis)
## Key Drug Interactions
* No significant drug interactions have been well-established.
## Monitoring
* Serum ammonia levels (baseline and periodically).
* Electrolytes.
* Renal and hepatic function tests.
* Clinical signs and symptoms of hepatic encephalopathy.
## Clinical Pearls
* L-ornithine L-aspartate is primarily indicated for the management of hyperammonemia associated with liver disease.
* Parenteral administration is the typical route for acute management.
* Infusion rate should be controlled to minimize adverse effects.
***
*Disclaimer: This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and institutional protocols before administering any medication. Dosing and recommendations may vary.*
